Production (Stage)
Drugs Made In America Acquisition Corp.
DMAA
$10.18
-$0.01-0.10%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 18.22% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 18.22% | ||||
| Operating Income | -18.22% | ||||
| Income Before Tax | 548.20% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 548.20% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 548.20% | ||||
| EBIT | -18.22% | ||||
| EBITDA | -- | ||||
| EPS Basic | 254.74% | ||||
| Normalized Basic EPS | 254.90% | ||||
| EPS Diluted | 250.46% | ||||
| Normalized Diluted EPS | 250.49% | ||||
| Average Basic Shares Outstanding | 189.22% | ||||
| Average Diluted Shares Outstanding | 197.60% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||